Pay in 4 interest-free payments of $7.09 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
PT-141 Key Research Facts: Rapid Reference 10 Things Researchers Should Know About PT-141 PT-141 Peptide is the only melanocortin receptor agonist with FDA approval for sexual dysfunction (in women, as Vyleesi) It acts centrally on the brain, not peripherally on blood vessels making it mechanistically distinct from all PDE-5 inhibitors Its primary targets are MC3R and MC4R in the hypothalamus Clinical trials involved 1,200+ premenopausal women, providing a robust safety and efficacy dataset The most common side effect is transient nausea, observed in approximately 40% of subjects PT-141 produces a temporary, dose-dependent increase in blood pressure (~6 mmHg systolic) Effects onset within 4560 minutes and can persist 1224 hours The compound was derived from Melanotan II, with the pigmentation mechanism removed PT-141 has no significant interaction with the PDE-5 enzyme it works through an entirely different pathway Research-grade PT-141 is available as a lyophilized powder requiring reconstitution with bacteriostatic water Conclusion: PT-141 (Bremelanotide) is not a peripheral compound or a trend-driven research curiosity
10.1016/j.amjcard.2015.12.031 21 DuJ.ZhangL.WangZ.YanoN.ZhaoY
Some compounders add ingredients such as vitamin B12, L-carnitine, or NAD+ NAD+ (nicotinamide adenine dinucleotide) A molecule every cell needs to make energy and repair DNA
It mimics a hormone (glucagon-like peptide-1) that your gut naturally releases after eating
US$ 25.82
US$ 25.46
US$ 22.84
US$ 22.80
US$ 25.05
US$ 23.09
